Trials and studies


Current trials and studies


The MAGNIFY MS Study evaluates how quickly oral cladribine (Mavenclad®) starts working. For this purpose, we will use magnetic resonance imaging (MRI). A total of ten (10) MRI head scans will be obtained over the course of two years. Knowing exactly at which time point a drug starts being effective is important for both people with MS as well as their care team so they all know what is likely going to happen over the first few months of treatment.  Around 300 participants in study centres worldwide will be involved.

  • The MAGNIFY MS Study is for people with relapsing MS over the age of 18. You must be diagnosed with “highly active” relapsing MS to be eligible. Your neurologist or MS nurse specialist will be able to tell whether this is the case.

There are further criteria that you need to meet in order to qualify, but please contact us if you would like to know more.

What does taking part involve?

The MAGNIFY MS Study will last 2 years from pre-screening through the last study visit. Throughout the 2 years, if you qualify for the study, you will attend 11 study visits in total and will be required to record certain information in a diary.


First, we will ask you about your health and run some tests to make sure that you are right for the study and confirm that the study is right for you. One of the tests will be a brain MRI scan.


If you pass screening and decide to enrol in the study, you will start treatment with Mavenclad® as per its European license. You will also undergo tests and procedures including a physical exam, having a blood sample taken, a neurological examination, and another brain MRI.

Study visits

After Baseline, you will visit the study center 9 times over 2 years, including eight further MRI scans

  1. ReLOAD-MS (Regulation of Lipid metabolism in Autoimmune Disease: Multiple Sclerosis)

This MS Society funded project explores the role of fats (such as cholesterol) in the body for the disease process of MS. Currently, we do not know how fats influence disease development. In this study we aim to understand of how fats in the body affect immune cells and how they are different in people with MS. Importantly, many of the molecules involved in the generation of fats are well known and for some of them drugs are already used in humans to treat diseases like arteriosclerosis and hypercholesterolemia (for example statins). This could allow the rapid translation of the results from this study to the clinic and have a direct impact for people with MS.

  1. MS Register

The MS Register is a nationwide study designed to increase our understanding of living with MS in the UK. We also expect it to help improve access to MS medicines and services.

Register online at

People with MS who are treated at one of our NHS partner sites can give their consent for their medical information to be securely transmitted to the Register. Their clinical details can be ‘linked’ to questionnaire results. This linked data creates an extremely rich source of information that can be used by researchers to help make sense of MS.

  1. LemtradaPASS

People with relapsing MS due to start treatment with Lemtrada® (alemtuzumab) should consider participation in this study evaluating the long term safety profile of this MS medicine

What is the main objective of the study?

To better characterize the long-term safety profile of Lemtrada in people with relapsing MS and to determine the frequency of Adverse Events of Special Interest (AESIs).

Such specific AESIs include serious infections, cancer, and auto-immune mediated conditions including idiopathic thrombocytopenic purpura (ITP), other conditions with low blood cell counts (cytopenias), thyroid disorders, and kidney diseases over a period of 5 years.

  1. TONiC(Trajectories of Outcome in Neurological Conditions)

TONiC is a nationwide study examining the factors that influence quality of life in people with neurological conditions. It is one of the largest studies on quality of life in neurological conditions ever performed in the UK.

Study website:

Upcoming trial and studies




For more information, please contact Kimberley Allen-Philbey (Clinical Trials Practitioner) at



Recent Posts

Recent Comments